Stock Taper
Aldeyra Therapeutics is a biotech firm developing immune-modulating medicines like reproxalap for ocular and systemic diseases, with multiple products in clinical trials for conditions such as dry eye, psoriasis, asthma, COVID-19, and retinal diso...

Reproxalap, Aldeyra's lead investigational small-molecule targeting RASP, is being developed for dry eye disease and allergic conjunctivitis, with a New Drug Application under review by the FDA.
Overall rating: C+
| PEER | PRICE | |
|---|---|---|
ANRO | $35.13 | COMPARE |
CADL | $13.07 | COMPARE |
CTNM | $17.05 | COMPARE |
SLN | $13.42 | COMPARE |
KYTX | $8.37 | COMPARE |
CLLS | $3.40 | COMPARE |
AMRN | $13.97 | COMPARE |
ACIU | $2.65 | COMPARE |